Results 171 to 180 of about 4,946 (233)

Exploring the Impact of Urolithins A and B on Muscle Health: A Transcriptomic Analysis in Human Myotubes

open access: yesJournal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 5, October 2026.
ABSTRACT Background Urolithin A (UA) and urolithin B (UB) are gut microbiota‐derived metabolites of ellagitannins reported to influence mitochondrial function, inflammation and muscle metabolism. Their comparative transcriptomic effects in human skeletal muscle cells remain undefined.
Yves Henrotin   +8 more
wiley   +1 more source

Total Immunoglobulin G Variation Through the Phenological Cycle of Migrant and Resident Lesser Long‐Nosed Bats (Leptonycteris yerbabuenae) in the Drylands of Mexico and Its Relationship With Bacterial Killing‐Ability of Plasma

open access: yesJournal of Experimental Zoology Part A: Ecological and Integrative Physiology, Volume 345, Issue 8, Page 832-849, October 2026.
ABSTRACT Bats have unique immunological characteristics among vertebrates. Understanding how the immune system responds during the life cycle of bat populations is crucial for grasping how their defenses against infection vary during critical life events.
David Alfonso Rivera‐Ruiz   +6 more
wiley   +1 more source

Immune dysregulation in the prostates of C57BL/6Aire−/− mice mirrors that seen in human benign prostatic hyperplasia

open access: yesThe Journal of Pathology, Volume 270, Issue 2, Page 211-225, October 2026.
Abstract Benign prostatic hyperplasia (BPH) is the most common urologic disease in aging men, resulting in significant morbidity. The etiologies of BPH are unknown, though chronic prostatic inflammation is known to promote hyperplasia, fibrotic remodeling, and therapeutic resistance in BPH.
Nadia A Lanman   +12 more
wiley   +1 more source

Clinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone‐Sensitive Prostate Cancer

open access: yesThe Prostate, Volume 86, Issue 14, Page 1461-1469, October 2026.
ABSTRACT Background Upfront treatment intensification with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor has become a standard approach for metastatic hormone‐sensitive prostate cancer (mHSPC). However, prognosis remains poor for some patients despite second‐generation androgen receptor antagonist‐based doublet therapy.
Saizo Fujimoto   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy